Curis to Present at Upcoming Healthcare Conference in July
Curis to Present at Upcoming Healthcare Conference in July
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with either a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML and MDS. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge to Genentech, a member of the Roche Group, under which they are commercializing Erivedge for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at LEXINGTON, Mass., July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the Jones Healthcare Seaside Summit 2024 on July 15, 2024 at 8:00 a.m. PT (11:00 a.m. ET). A live webcast and archived replay will be available and can be accessed here or on the Events & Presentations section of Curis's website.
2024年7月10日，馬薩諸塞州列剋星敦 / PRNewswire - 生物技術公司Curis，Inc.（NASDAQ：CRIS）專注於開發口服小分子IRAK4抑制劑emavusertib（CA-4948），今天宣佈，Curis的總裁兼首席執行官James Dentzer將於2024年7月15日上午8:00（太平洋時間），下午11:00（東部時間）在Jones Healthcare Seaside Summit 2024上發表演講。可在線收聽直播和歸檔重播，點擊此處或訪問Curis網站的活動與演示部分。
About Curis, Inc.
關於Curis，Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with either a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML and MDS. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge to Genentech, a member of the Roche Group, under which they are commercializing Erivedge for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at
Curis是一家生物技術公司，致力於開發口服小分子IRAK4抑制劑emavusertib。emavusertib目前正在進行第1/2期TakeAim淋巴瘤研究，研究對象是患有複發性/難治性原發性中樞神經系統淋巴瘤（PCNSL）的患者，在與BTk抑制劑ibrutinib聯合使用的情況下，作爲單藥用於複發性/難治性急性髓細胞白血病（AML）和攜帶FLT3突變或剪接因子突變（U2AF1或SF3B2）的高危骨髓增生異常綜合徵（hrMDS）患者的第1/2期TakeAim白血病研究，以及與azacitidine和venetoclax合併用於AML患者的一線組合療法。emavusertib已獲得美國食品和藥物管理局授予的治療AML和MDS的孤兒藥物認證。Curis通過與Aurigene的2015年合作擁有emavusertib (CA-4948) 的獨家許可。Curis已將其對Erivedge的權利許可給了Roche旗下的Genentech，用於開發用於治療晚期基底細胞癌的Erivedge。更多信息，請訪問Curis網站的網站。
SOURCE Curis, Inc.
來源：Curis股份有限公司。
